BNN Brain Biotechnology Research and Information Network AG

EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM
Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

18.03.2025 / 16:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG

ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and Stephen Catling were re-elected to the Supervisory Board.

At the time of voting 63,8 % of the share capital was represented.

Dr. Michael Majerus, Chairman of the Supervisory Board, stated: "I am particularly pleased that the Annual General Meeting elected Dr. Anna Eichhorn and Mr. Stephen Catling to the Supervisory Board for an additional term. With their outstanding expertise, both are an integral part of the Supervisory Board's work. Majerus continued: "In the past financial year 2023/24, we were able to successfully prepare and conclude two benchmark transactions together with the Executive Board and thus significantly advance the Company's strategic development."

With the publication of the 3M numbers for the financial year 2024/25, the company forecast for the full year a high single-digit to low double-digit percentage increase in sales and an adjusted EBITDA margin of around 10 % in the core segment BRAINBiocatalysts.

In his address to shareholders, CEO Adriaan Moelker said: “Last year was in many respects a year of execution for BRAIN Biotech, as we prepared our path to consistently deliver on our goals. We announced the agreement with Royalty Pharma, which can bring BRAIN Biotech up to 129 million Euro in cash. Shortly thereafter, we announced the licensing agreement with Akribion Therapeutics. Taken together, these two transactions represent tremendous value for our shareholders.”

The detailed voting results and all other documents relating to the Annual General Meeting are available on the website of BRAIN Biotech AG: .

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: -biotech-group.com.

 

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: 0
Email:

 

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: 9
Email:

 

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Group

Web:

LinkedIn:

Threads:

Bluesky:

X:

Youtube:

 

Biocatalysts Ltd (Production, Distribution)

Website:

LinkedIn: /

 

BRAIN Biotech Zwingenberg (Technologies & R&D Services)

Website:

LinkedIn:

 

AnalyticonDiscovery (R&D)

Web:

LinkedIn:

 

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

 

 



18.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail:
Internet: -biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2102590

 
End of News EQS News Service

2102590  18.03.2025 CET/CEST

EN
18/03/2025

Underlying

Reports on Brain Biotechnology Research and Information Network AG

 PRESS RELEASE

EQS-News: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 ...

EQS-News: BRAIN Biotech AG / Schlagwort(e): Hauptversammlung Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG 18.03.2025 / 16:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG ZWINGENBERG, 18. März 2025 – In der ordentlichen Präsenzhauptversammlung der BRAIN Biotech AG (Frankfurter Börse / BNN / ISIN DE0005203947 / WKN 5203949) haben die Aktionäre heute allen Tagesordnungspunkten mit einer breiten Mehrheit zugestimmt. Dr....

 PRESS RELEASE

EQS-News: Results of the 2025 Annual General Meeting for the 2023/24 f...

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG 18.03.2025 / 16:45 CET/CEST The issuer is solely responsible for the content of this announcement. Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Anna C. Eichhorn and S...

BRAIN Biotech AG: 1 director

A director at BRAIN Biotech AG bought 10,000 shares at 2.500EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

EQS-News: BRAIN Biotech AG: 3M FY 24/25 - Starting the year with doubl...

EQS-News: BRAIN Biotech AG / Key word(s): Quarterly / Interim Statement BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division 26.02.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25 S...

 PRESS RELEASE

EQS-News: BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelli...

EQS-News: BRAIN Biotech AG / Schlagwort(e): Quartals-/Zwischenmitteilung BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts 26.02.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts BRAINBiocatalysts mit 11 % organischem Wachstum im ersten Quartal Quantitative Prognose für starkes Wachstum und solide bereinigte EBITDA-Marge für BRAINBiocatalysts im Gesch...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch